PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 163 filers reported holding PDL BIOPHARMA INC in Q2 2018. The put-call ratio across all filers is 1.66 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $122,000 | -13.5% | 38,671 | -20.4% | 0.00% | – |
Q2 2020 | $141,000 | +6.8% | 48,591 | +3.4% | 0.00% | – |
Q1 2020 | $132,000 | -18.0% | 47,008 | -5.4% | 0.00% | – |
Q4 2019 | $161,000 | -30.0% | 49,716 | -53.4% | 0.00% | – |
Q3 2019 | $230,000 | -78.9% | 106,630 | -69.3% | 0.00% | – |
Q2 2019 | $1,092,000 | -76.6% | 347,638 | -72.2% | 0.00% | -100.0% |
Q1 2019 | $4,658,000 | +469.4% | 1,252,208 | +343.4% | 0.00% | – |
Q4 2018 | $818,000 | +240.8% | 282,404 | +209.2% | 0.00% | – |
Q3 2018 | $240,000 | -87.5% | 91,325 | -88.8% | 0.00% | – |
Q2 2018 | $1,914,000 | +398.4% | 818,011 | +525.0% | 0.00% | – |
Q1 2018 | $384,000 | -31.6% | 130,872 | -36.2% | 0.00% | – |
Q4 2017 | $561,000 | +8.7% | 205,083 | +34.9% | 0.00% | – |
Q3 2017 | $516,000 | -88.4% | 152,075 | -91.6% | 0.00% | -100.0% |
Q2 2017 | $4,459,000 | +1267.8% | 1,805,182 | +1157.6% | 0.00% | – |
Q1 2017 | $326,000 | +28.3% | 143,544 | +19.8% | 0.00% | – |
Q4 2016 | $254,000 | -24.2% | 119,846 | +19.7% | 0.00% | – |
Q3 2016 | $335,000 | -64.7% | 100,111 | -66.8% | 0.00% | – |
Q2 2016 | $949,000 | -0.3% | 301,906 | +5.6% | 0.00% | – |
Q1 2016 | $952,000 | -63.3% | 285,827 | -61.0% | 0.00% | – |
Q4 2015 | $2,595,000 | -26.4% | 733,111 | +4.5% | 0.00% | -100.0% |
Q3 2015 | $3,528,000 | -22.1% | 701,559 | -0.3% | 0.00% | 0.0% |
Q2 2015 | $4,526,000 | -4.3% | 703,735 | +4.6% | 0.00% | 0.0% |
Q1 2015 | $4,731,000 | -87.4% | 672,603 | -86.2% | 0.00% | -92.3% |
Q4 2014 | $37,589,000 | +11.6% | 4,875,328 | +8.1% | 0.01% | +18.2% |
Q3 2014 | $33,685,000 | +78.3% | 4,509,433 | +131.0% | 0.01% | +83.3% |
Q2 2014 | $18,894,000 | -13.8% | 1,951,877 | -26.0% | 0.01% | -25.0% |
Q1 2014 | $21,908,000 | -4.4% | 2,636,319 | -2.9% | 0.01% | 0.0% |
Q4 2013 | $22,921,000 | -13.5% | 2,715,760 | -18.3% | 0.01% | -27.3% |
Q3 2013 | $26,508,000 | +21.9% | 3,325,999 | +18.1% | 0.01% | +22.2% |
Q2 2013 | $21,740,000 | – | 2,816,011 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |